Amendment No. 1 to At Market Issuance Sales AgreementSales Agreement • April 14th, 2015 • Peregrine Pharmaceuticals Inc • Pharmaceutical preparations • New York
Reference is made to the At Market Issuance Sales Agreement, dated June 13, 2014, including the Schedules thereto, relating to the sale and issuance of common stock (the “Sales Agreement”), between MLV & Co. LLC (“MLV”) and Peregrine Pharmaceuticals, Inc., a Delaware corporation (the “Company”). All capitalized terms used in this Amendment No. 1 to At Market Issuance Sales Agreement between MLV and the Company (this “Amendment”) and not otherwise defined herein shall have the respective meanings assigned to such terms in the Sales Agreement. MLV and the Company agree as follows:
